Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Non-Current Receivables (2019 - 2021)

Vivos Therapeutics has reported Non-Current Receivables over the past 3 years, most recently at $842290.0 for Q3 2021.

  • Quarterly Non-Current Receivables changed N/A to $842290.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $842290.0 through Sep 2021, changed N/A year-over-year, with the annual reading at $811000.0 for FY2020, 3.3% up from the prior year.
  • Non-Current Receivables was $842290.0 for Q3 2021 at Vivos Therapeutics, roughly flat from $846214.0 in the prior quarter.
  • Over five years, Non-Current Receivables peaked at $846214.0 in Q2 2021 and troughed at $785061.0 in Q4 2019.
  • The 3-year median for Non-Current Receivables is $816584.0 (2021), against an average of $820229.8.
  • The largest YoY upside for Non-Current Receivables was 3.3% in 2020 against a maximum downside of 3.3% in 2020.
  • A 3-year view of Non-Current Receivables shows it stood at $785061.0 in 2019, then grew by 3.3% to $811000.0 in 2020, then rose by 3.86% to $842290.0 in 2021.
  • Per Business Quant, the three most recent readings for VVOS's Non-Current Receivables are $842290.0 (Q3 2021), $846214.0 (Q2 2021), and $816584.0 (Q1 2021).